PDF herunterladen
Semin Thromb Hemost 2022; 48(04): 481-489
DOI: 10.1055/s-0041-1733923
Review Article

Cardiovascular Mortality after Venous Thromboembolism: A Meta-Analysis of Prospective Cohort Studies

Steve Raoul Noumegni
1   Department of Vascular Medicine, Brest Teaching Hospital, Brest, France
2   EA3878 (GETBO), Western Brittany Thrombosis Study Group, Brest University, Brest, France
,
Thomas Grangereau
1   Department of Vascular Medicine, Brest Teaching Hospital, Brest, France
3   Department of Cardiovascular Medicine, Guingamp Hospital, Guingamp, France
,
Arzu Demir
4   Department of Vascular Medicine, Bordeaux Teaching Hospital, Bordeaux, France
,
Luc Bressollette
1   Department of Vascular Medicine, Brest Teaching Hospital, Brest, France
2   EA3878 (GETBO), Western Brittany Thrombosis Study Group, Brest University, Brest, France
,
Francis Couturaud
2   EA3878 (GETBO), Western Brittany Thrombosis Study Group, Brest University, Brest, France
5   Department of Internal Medicine and Pneumology, Brest Teaching Hospital, Brest, France
,
Clément Hoffmann
1   Department of Vascular Medicine, Brest Teaching Hospital, Brest, France
2   EA3878 (GETBO), Western Brittany Thrombosis Study Group, Brest University, Brest, France
› Institutsangaben Funding None.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Many studies from current literature show that cardiovascular diseases in patients with venous thromboembolism (VTE) are more frequent than in the general population without VTE. However, data summarizing the impact of cardiovascular diseases on mortality of patients with VTE are lacking. In this systematic review and meta-analysis, we aimed to determine the frequency and incidence rate of cardiovascular death in patients with VTE. MEDLINE and EMBASE were searched from January 1, 2000 to February 28, 2021. Eligible studies were observational prospective cohort studies including patients with VTE and reporting all causes of death. Cardiovascular death was defined as deaths that result from new or recurrent pulmonary embolism, death due to acute myocardial infarction, sudden cardiac death or heart failure, death due to stroke, death due to cardiovascular procedures or hemorrhage, death due to ruptured aortic aneurysm or aortic dissection and death due to other cardiovascular causes. Random-effect models meta-analysis served to determine all pooled effect size of interest with their 95% confidence interval (CI). Thirteen observational studies enrolling 22,251 patients were identified and included. The mean/median age varied between 49 and 75 years. The proportion of men ranged from 38.3 to 53.2%. The overall pooled frequency of cardiovascular death in patients with VTE was 3.9% (95% CI: 2.5–5.6%), while the overall pooled frequency of all-cause mortality was 12.0% (95% CI: 9.1–15.4%). The pooled proportion of cardiovascular death among all causes of deaths in patients with VTE was 35.2% (95% CI: 22.2–49.3%). The pooled incidence rate of cardiovascular death was 1.92 per 100 patient-years (95% CI: 0–4.1). The frequency of cardiovascular death in patients with VTE was significantly higher than in patients without VTE (risk ratio: 3.85, 95% CI: 2.75–5.39). Based on this updated meta-analysis from 13 prospective cohort studies, cardiovascular death in patients with VTE is more frequent than in the general population without VTE.

Keywords

cardiovascular mortality - cardiovascular death - venous thromboembolism - frequency - incidence - meta-analysis

Authors' Contributions

S.R.N., F.C., and L.B. contributed toward the conception and designing of the protocol. S.R.N. and T.G. did the literature search, studies selection, and data extraction. S.R.N. wrote the first draft and did the data management, data synthesis, and analysis. All the authors did the critical revision. S.R.N., T.G., A.D., and C.H. performed final revision and approved the final version. S.R.N. was the guarantor of the review.


Supplementary Material



Publikationsverlauf

Artikel online veröffentlicht:
08. Oktober 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 3-14
    CrossrefPubMedGoogle Scholar
  • 2 Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38 (Suppl. 04) S495-S501
    CrossrefPubMedGoogle Scholar
  • 3 Adelborg K, Sundbøll J, Sørensen HT. Arterial cardiovascular events and mortality following venous thromboembolism. Ann Transl Med 2015; 3 (09) 117
    PubMedGoogle Scholar
  • 4 Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010; 8 (05) 891-897
    CrossrefPubMedGoogle Scholar
  • 5 Young L, Ockelford P, Milne D, Rolfe-Vyson V, Mckelvie S, Harper P. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4 (09) 1919-1924
    CrossrefPubMedGoogle Scholar
  • 6 Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370 (9601): 1773-1779
    CrossrefPubMedGoogle Scholar
  • 7 Roth GA, Johnson C, Abajobir A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70 (01) 1-25
    CrossrefPubMedGoogle Scholar
  • 8 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (03) 320-328
    CrossrefPubMedGoogle Scholar
  • 9 Ng ACC, Chung T, Yong ASC. et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011; 4 (01) 122-128
    CrossrefPubMedGoogle Scholar
  • 10 Castelli R, Bucciarelli P, Porro F, Depetri F, Cugno M. Pulmonary embolism in elderly patients: prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality. Thromb Res 2014; 134 (02) 326-330
    CrossrefPubMedGoogle Scholar
  • 11 Huerta C, Johansson S, Wallander M-A, Rodríguez LAG. Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism. Thromb J 2008; 6: 10
    CrossrefPubMedGoogle Scholar
  • 12 Chuang L-H, Gumbs P, van Hout B. et al. Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Qual Life Res 2019; 28 (08) 2111-2124
    CrossrefPubMedGoogle Scholar
  • 13 Brenner B, Bikdeli B, Tzoran I. et al; RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism. Am J Med 2018; 131 (09) 1095-1103
    CrossrefPubMedGoogle Scholar
  • 14 Faller N, Limacher A, Méan M. et al. Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: a prospective cohort study. Am J Med 2017; 130 (02) 198-206
    CrossrefPubMedGoogle Scholar
  • 15 Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Calvo-Rojas G, Vargas-Castrillón E. Causes of death in patients with venous thromboembolism anticoagulated with direct oral anticoagulants: a systematic review and meta-analysis. Semin Thromb Hemost 2018; 44 (04) 377-387
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 16 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6 (07) e1000100
    CrossrefPubMedGoogle Scholar
  • 17 Hicks KA, Mahaffey KW, Mehran R. et al; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol 2018; 71 (09) 1021-1034
    CrossrefPubMedGoogle Scholar
  • 18 Hicks KA, Tcheng JE, Bozkurt B. et al; ACC/AHA TASK FORCE ON CLINICAL DATA STANDARDS MEMBERS. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol 2015; 22 (05) 1041-1144
    CrossrefPubMedGoogle Scholar
  • 19 Hartling L, Hamm M, Milne A. et al. Decision Rules for Application of the Newcastle-Ottawa Scale, Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments. Agency for Healthcare Research and Quality (US). 2012 . Accessed January 21, 2021 at: https://www.ncbi.nlm.nih.gov/books/NBK92291/
    PubMedGoogle Scholar
  • 20 Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10 (01) 101-129
    CrossrefPubMedGoogle Scholar
  • 21 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21 (11) 1539-1558
    Google Scholar
  • 22 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315 (7109): 629-634
    Google Scholar
  • 23 Monreal M, Agnelli G, Chuang LH. et al. Deep vein thrombosis in Europe-health-related quality of life and mortality. Clin Appl Thromb Hemost 2019; 25: 1076029619883946
    CrossrefPubMedGoogle Scholar
  • 24 Ģībietis V, Kigitoviča D, Vītola B, Strautmane S, Skride A. Glomerular filtration rate as a prognostic factor for long-term mortality after acute pulmonary embolism. Med Princ Pract 2019; 28 (03) 264-272
    CrossrefPubMedGoogle Scholar
  • 25 Alonso-Martínez JL, Annicchérico-Sánchez FJ, Urbieta-Echezarreta MA, Pérez-Ricarte S. N-terminal Pro-B type natriuretic peptide as long-term predictor of death after an acute pulmonary embolism. Med Clin (Barc) 2015; 144 (06) 241-246
    CrossrefPubMedGoogle Scholar
  • 26 Roach REJ, Lijfering WM, Flinterman LE, Rosendaal FR, Cannegieter SC. Increased risk of CVD after VT is determined by common etiologic factors. Blood 2013; 121 (24) 4948-4954
    CrossrefPubMedGoogle Scholar
  • 27 Prandoni P, Ghirarduzzi A, Prins MH. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4 (09) 1891-1896
    CrossrefPubMedGoogle Scholar
  • 28 Becattini C, Agnelli G, Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26 (01) 77-83
    CrossrefPubMedGoogle Scholar
  • 29 La Vecchia L, Ottani F, Favero L. et al. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart 2004; 90 (06) 633-637
    CrossrefPubMedGoogle Scholar
  • 30 Lind C, Flinterman LE, Enga KF. et al. Impact of incident venous thromboembolism on risk of arterial thrombotic diseases. Circulation 2014; 129 (08) 855-863
    CrossrefPubMedGoogle Scholar
  • 31 Ljungqvist M, Holmström M, Kieler H, Odeberg J, Lärfars G. Cardiovascular disease and mortality after a first episode of venous thromboembolism in young and middle-aged women. Thromb Res 2016; 138: 80-85
    CrossrefPubMedGoogle Scholar
  • 32 Madridano O, del Toro J, Lorenzo A. et al; RIETE Investigators. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. J Vasc Surg Venous Lymphat Disord 2015; 3 (02) 135-41.e1
    CrossrefPubMedGoogle Scholar
  • 33 Chang W-T, Chang C-L, Ho C-H, Hong C-S, Wang J-J, Chen Z-C. Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events. J Am Heart Assoc 2017; 6 (05) e005466
    CrossrefPubMedGoogle Scholar